Christopher R. McCurdy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher R. McCurdy has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Gwénaël Chevé
OriBase Pharma
3 shared publications Jacques H. Poupaert
Université Catholique de Louvain, 74 Avenue Emmanuel Mounier, B-1200 Brussels, Belgium
3 shared publicationsNidhi Singh
Department of Medicinal Chemistry, Laboratory for Applied Drug Design and Synthesis, University of Mississippi, University, MS, 38677-1848, USA
3 shared publicationsChristophe Mésangeau
Department of BioMolecular Sciences, School of Pharmacy, The University of Mississippi, University, Mississippi 38677, United States
2 shared publicationsKenneth J. Sufka
National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, MS 38677, USA; Department of Psychology, College of Liberal Arts, The University of Mississippi, MS 38677, USA
2 shared publicationsRae R. Matsumoto
Department of Basic Pharmaceutical Sciences, West Virginia University, Morgantown, WV 26506, USA
2 shared publications
Latest Publications
- 1 July 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (13) , 3248-3259
Design, synthesis and biological evaluation of bivalent benzoxazolone and benzothiazolone ligands as potential anti-inflammatory/analgesic agents
- 1 July 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (13) , 3248-3259
Design, synthesis and biological evaluation of bivalent benzoxazolone and benzothiazolone ligands as potential anti-inflammatory/analgesic agents
- Open Access
- 21 October 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (21) , 8903-8927
Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors
Neuropeptide FF1 and FF2 receptors (NPFF1-R and NPFF2-R), and their endogenous ligand NPFF, are one of only several systems responsible for mediating opioid-induced hyperalgesia, tolerance, and dependence. Currently, no small molecules displaying good affinity or selectivity for either subtype have been reported, to decipher the role of NPFF2-R as it relates to opioid-mediated analgesia, for further exploration of NPFF1-R, or for medication development for either subtype. We report the first nonpeptide small molecule scaffold for NPFF1,2-R, the guanidino-piperidines, and SAR studies resulting in the discovery of a NPFF1 agonist (7b, Ki = 487 ± 117 nM), a NPFF1 antagonist (46, Ki = 81 ± 17 nM), and a NPFF2 partial antagonist (53a, Ki = 30 ± 5 nM), which serve as leads for the development of pharmacological probes and potential therapeutic agents. Testing of 46 alone was without effect in the mouse 48 °C warm-water tail-withdrawal test, but pretreatment with 46 prevented NPFF-induced hyperalgesia.
- 21 October 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (21) , 8903-8927
Open AccessNonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors
Neuropeptide FF1 and FF2 receptors (NPFF1-R and NPFF2-R), and their endogenous ligand NPFF, are one of only several systems responsible for mediating opioid-induced hyperalgesia, tolerance, and dependence. Currently, no small molecules displaying good affinity or selectivity for either subtype have been reported, to decipher the role of NPFF2-R as it relates to opioid-mediated analgesia, for further exploration of NPFF1-R, or for medication development for either subtype. We report the first nonpeptide small molecule scaffold for NPFF1,2-R, the guanidino-piperidines, and SAR studies resulting in the discovery of a NPFF1 agonist (7b, Ki = 487 ± 117 nM), a NPFF1 antagonist (46, Ki = 81 ± 17 nM), and a NPFF2 partial antagonist (53a, Ki = 30 ± 5 nM), which serve as leads for the development of pharmacological probes and potential therapeutic agents. Testing of 46 alone was without effect in the mouse 48 °C warm-water tail-withdrawal test, but pretreatment with 46 prevented NPFF-induced hyperalgesia.
- 1 September 2013
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (17) , 5011-5013
Structure activity relationship study of benzo[d]thiazol-2(3H)one based σ receptor ligands
- 1 September 2013
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (17) , 5011-5013
Structure activity relationship study of benzo[d]thiazol-2(3H)one based σ receptor ligands
- 18 June 2012
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 4 (9) , 1085-1092
Nonpeptide Ligands of Neuropeptide FF: Current Status and Structural Insights
Neuropeptide FF (NPFF) was first isolated from the bovine brain in 1985 and is linked with a variety of biological activities. NPFF, which belongs to the RF-amide family of peptides, interacts with two distinct G-protein-coupled receptors, NPFF1 and NPFF2. These receptors are distributed throughout the body. The NPFF system was initially described as an anti-opioid system and, while the NPFF system does affect the opioid system, it also has been implicated in pain modulation, changes in arterial blood pressure, feeding behavior and regulation of core body temperature and of monoamine systems. Most of this pharmacology has been realized from the peptide NPFF itself or through peptide analogs. The quest for nonpeptide tools for this receptor system has been limited by low selectivity and poor pharmacokinetic properties. Herein, we summarize the current knowledge from the scientific and patent literature that demonstrates a clear need for future medicinal chemistry efforts.
- 18 June 2012
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 4 (9) , 1085-1092
Nonpeptide Ligands of Neuropeptide FF: Current Status and Structural Insights
Neuropeptide FF (NPFF) was first isolated from the bovine brain in 1985 and is linked with a variety of biological activities. NPFF, which belongs to the RF-amide family of peptides, interacts with two distinct G-protein-coupled receptors, NPFF1 and NPFF2. These receptors are distributed throughout the body. The NPFF system was initially described as an anti-opioid system and, while the NPFF system does affect the opioid system, it also has been implicated in pain modulation, changes in arterial blood pressure, feeding behavior and regulation of core body temperature and of monoamine systems. Most of this pharmacology has been realized from the peptide NPFF itself or through peptide analogs. The quest for nonpeptide tools for this receptor system has been limited by low selectivity and poor pharmacokinetic properties. Herein, we summarize the current knowledge from the scientific and patent literature that demonstrates a clear need for future medicinal chemistry efforts.
- 1 October 2011
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 46 (10) , 5154-5161
Synthesis and pharmacological evaluation of indole-based sigma receptor ligands
- 1 October 2011
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 46 (10) , 5154-5161
Synthesis and pharmacological evaluation of indole-based sigma receptor ligands
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S123-S124
[18F]FTC-146: A novel and highly selective PET ligand for visualizing sigma-1 receptors in living subjects
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S123-S124
[18F]FTC-146: A novel and highly selective PET ligand for visualizing sigma-1 receptors in living subjects
- Open Access
- 29 May 2009
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section E Crystallographic Communications
- Vol. 65 (6) , o1441-o1442
(E)-Methyl 2-[(2S,3S,12bR)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyacrylate ethanol solvate
In the title compound, C23H30N2O4·C2H6O, the indole derivative has four fused rings, forming an indolo[2-3a]quinolizine system, in which one six-membered ring is directly connected to the indole unit and has a distorted chair conformation. The fourth ring is also a six-membered ring, depicting a regular chair conformation. In the crystal, the molecules are linked by N—H...O and O—H...N interactions, forming aC(7) chain.
- 29 May 2009
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section E Crystallographic Communications
- Vol. 65 (6) , o1441-o1442
Open Access(E)-Methyl 2-[(2S,3S,12bR)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyacrylate ethanol solvate
In the title compound, C23H30N2O4·C2H6O, the indole derivative has four fused rings, forming an indolo[2-3a]quinolizine system, in which one six-membered ring is directly connected to the indole unit and has a distorted chair conformation. The fourth ring is also a six-membered ring, depicting a regular chair conformation. In the crystal, the molecules are linked by N—H...O and O—H...N interactions, forming aC(7) chain.
- 14 September 2007
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 21 (9) , 511-522
Toward Mycobacterium tuberculosis DXR inhibitor design: homology modeling and molecular dynamics simulations
Mycobacterium tuberculosis 1-deoxy-d-xylulose-5-phosphate reductoisomerase (MtDXR) is a potential target for antitubercular chemotherapy. In the absence of its crystallographic structure, our aim was to develop a structural model of MtDXR. This will allow us to gain early insight into the structure and function of the enzyme and its likely binding to ligands and cofactors and thus, facilitate structure-based inhibitor design. To achieve this goal, initial models of MtDXR were generated using MODELER. The best quality model was refined using a series of minimizations and molecular dynamics simulations. A protein–ligand complex was also developed from the initial homology model of the target protein by including information about the known ligand as spatial restraints and optimizing the mutual interactions between the ligand and the binding site. The final model was evaluated on the basis of its ability to explain several site-directed mutagenesis data. Furthermore, a comparison of the homology model with the X-ray structure published in the final stages of the project shows excellent agreement and validates the approach. The knowledge gained from the current study should prove useful in the design and development of inhibitors as potential novel therapeutic agents against tuberculosis by either de novo drug design or virtual screening of large chemical databases.
- 14 September 2007
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 21 (9) , 511-522
Toward Mycobacterium tuberculosis DXR inhibitor design: homology modeling and molecular dynamics simulations
Mycobacterium tuberculosis 1-deoxy-d-xylulose-5-phosphate reductoisomerase (MtDXR) is a potential target for antitubercular chemotherapy. In the absence of its crystallographic structure, our aim was to develop a structural model of MtDXR. This will allow us to gain early insight into the structure and function of the enzyme and its likely binding to ligands and cofactors and thus, facilitate structure-based inhibitor design. To achieve this goal, initial models of MtDXR were generated using MODELER. The best quality model was refined using a series of minimizations and molecular dynamics simulations. A protein–ligand complex was also developed from the initial homology model of the target protein by including information about the known ligand as spatial restraints and optimizing the mutual interactions between the ligand and the binding site. The final model was evaluated on the basis of its ability to explain several site-directed mutagenesis data. Furthermore, a comparison of the homology model with the X-ray structure published in the final stages of the project shows excellent agreement and validates the approach. The knowledge gained from the current study should prove useful in the design and development of inhibitors as potential novel therapeutic agents against tuberculosis by either de novo drug design or virtual screening of large chemical databases.
- 26 July 2007
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 16 (3) , 130-135
Structure–activity relationship of phenytoinergic antiepileptic drugs related to ameltolide
- 26 July 2007
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 16 (3) , 130-135
Structure–activity relationship of phenytoinergic antiepileptic drugs related to ameltolide
- 29 September 2006
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 20 (7-8) , 471-493
A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist
Combined ligand-based and target-based drug design approaches provide a synergistic advantage over either method individually. Therefore, we set out to develop a powerful virtual screening model to identify novel molecular scaffolds as potential leads for the human KOP (hKOP) receptor employing a combined approach. Utilizing a set of recently reported derivatives of salvinorin A, a structurally unique KOP receptor agonist, a pharmacophore model was developed that consisted of two hydrogen bond acceptor and three hydrophobic features. The model was cross-validated by randomizing the data using the CatScramble technique. Further validation was carried out using a test set that performed well in classifying active and inactive molecules correctly. Simultaneously, a bovine rhodopsin based “agonist-bound” hKOP receptor model was also generated. The model provided more accurate information about the putative binding site of salvinorin A based ligands. Several protein structure-checking programs were used to validate the model. In addition, this model was in agreement with the mutation experiments carried out on KOP receptor. The predictive ability of the model was evaluated by docking a set of known KOP receptor agonists into the active site of this model. The docked scores correlated reasonably well with experimental pK i values. It is hypothesized that the integration of these two independently generated models would enable a swift and reliable identification of new lead compounds that could reduce time and cost of hit finding within the drug discovery and development process, particularly in the case of GPCRs.
- 29 September 2006
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 20 (7-8) , 471-493
A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist
Combined ligand-based and target-based drug design approaches provide a synergistic advantage over either method individually. Therefore, we set out to develop a powerful virtual screening model to identify novel molecular scaffolds as potential leads for the human KOP (hKOP) receptor employing a combined approach. Utilizing a set of recently reported derivatives of salvinorin A, a structurally unique KOP receptor agonist, a pharmacophore model was developed that consisted of two hydrogen bond acceptor and three hydrophobic features. The model was cross-validated by randomizing the data using the CatScramble technique. Further validation was carried out using a test set that performed well in classifying active and inactive molecules correctly. Simultaneously, a bovine rhodopsin based “agonist-bound” hKOP receptor model was also generated. The model provided more accurate information about the putative binding site of salvinorin A based ligands. Several protein structure-checking programs were used to validate the model. In addition, this model was in agreement with the mutation experiments carried out on KOP receptor. The predictive ability of the model was evaluated by docking a set of known KOP receptor agonists into the active site of this model. The docked scores correlated reasonably well with experimental pK i values. It is hypothesized that the integration of these two independently generated models would enable a swift and reliable identification of new lead compounds that could reduce time and cost of hit finding within the drug discovery and development process, particularly in the case of GPCRs.